

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/722,115	11/25/2003	Steven D. Girouard	279.597US1	4851	
21186 7590 07/13/2007 SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.		EXAM	EXAMINER		
P.O. BOX 2938			· BEISNER, WILLIAM H		
MINNEAPOL	IS, MN 55402		ART UNIT PAPER NUMBER		
			. 1744		
		·	MAIL DATE .	DELIVERY MODE	
			07/13/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
Advisory Action	10/722,115	GIROUARD ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	1
z erest are t am g er am t pp em z	William H. Beisner	1744	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	lress
THE REPLY FILED <u>03 July 2007</u> FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR AL	LOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in complian time periods:	owing replies: (1) an amendment, af otice of Appeal (with appeal fee) in once with 37 CFR 1.114. The reply m	fidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
 a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this a no event, however, will the statutory period for reply expire 	Advisory Action, or (2) the date set forth	in the final rejection, wh	nichever is later. In
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	(b). ONLY CHECK BOX (b) WHEN TH	E FIRST REPLY WAS F	FILED WITHIN
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	xtension and the corresponding amount shortened statutory period for reply origor than three months after the mailing days.	of the fee. The appropr pinally set in the final Offi ate of the final rejection,	riate extension fee ice action; or (2) as even if timely filed,
 The Notice of Appeal was filed on A brief in comfiling the Notice of Appeal (37 CFR 41.37(a)), or any extension a Notice of Appeal has been filed, any reply must be filed. 	ension thereof (37 CFR 41.37(e)), to	o avoid dismissal of th	
AMENDMENTS	hara antara a abar da a a fillioni a bata a		
 The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further compared to the first the issue of new matter (see NOTE below). They are not deemed to place the application in beautiful appeal; and/or (d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)) 	onsideration and/or search (see NC ow); etter form for appeal by materially re a corresponding number of finally re	TE below); educing or simplifying	
4. The amendments are not in compliance with 37 CFR 1.	121. See attached Notice of Non-Co	ompliant Amendment	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s			
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proposed amendment (s): a) how the new or amended claims would be rejected is proposed amendment (s): a) how the new or amended claims would be rejected is proposed amendment (s): a) how the new or amendment (s): a) how the status of the claims will be as follows: Claim(s) allowed: Claim(s) withdrawn from consideration:) ∐ will not be entered, or b) ⊠ wovided below or appended.	ill be entered and an	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good at was not earlier presented. See 37 CFR 1.116(e).	out before or on the date of filing a N nd sufficient reasons why the affida	lotice of Appeal will <u>no</u> vit or other evidence i	ot be entered is necessary and
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome all rejections under appe	eal and/or appellant fa	ils to provide a
10. \square The affidavit or other evidence is entered. An explanating REQUEST FOR RECONSIDERATION/OTHER		•	
11. \square The request for reconsideration has been considered by	out does NOT place the application	in condition for allowa	ince because:
12. ☐ Note the attached Information Disclosure Statement(s) 13. ☒ Other: See Continuation Sheet.	. (PTO/SB/08) Paper No(s)		

Milliam H. Beisner/ Primary Examiner Art Unit: 1744

Application No. 10/722,115

Continuation of 13. Other: Amended claim 1 and new claims 76-79 as well as claims 2-10, 12-14 and 7-75 are rejected over the combination of the references of Dennis et al. (US 6,114,164) in view of Kofidis et al. (Journal of Thoracic and Cardio. Surg.), Farb et al.(US 6,048,722), Bursac et al.(Am. J. Physiol. 277) and Terracio et al.(In Vitro Cell. and Develop. Bio.) for the same reasons as set forth in section (5) of the Final Office Action dated 4/4/2007. Claim 1 is rejected for the same reasons set forth with respect to canceled claim 72 and claims 76-79 are rejectable because the controller resulting from the combination of the references discussed in the rejection are structurally capable of providing the control and/or processing required of claims 76-79. With respect to amended claim 1, Applicants argue that the rejection is improper because "Applicant is unable to find in the cited portions of Dennis, Kofidis, Farb, Bursac, and Terracio, individually or in combination, among other things, a memory circuit including an instruction set adapted to condition cells for administration into tissue of myocardium, the instruction set defining a predetermined sequence of one or more electrical, mechanical, and biological stimuli, and a controller adapted to control the cardiac electrical stimulator, the myocardial stress simulator, and the biological treatment administration module by automatically executing the instruction set". Applicants stress that none of the recited references In response to applicant's arguments against the references individually, one cannot show disclose this specific claim language. 1. nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In this case, the reference of Dennis et al. discloses a controller and user interface (52) that includes input devices, memory and display which allow manipulation of the conditions within the system. The additional references as discussed in the rejection of record provide the motivation for controlling the different stimulation devices for emulating the conditions found in vivo. As a result, an apparatus programmed as suggested in the rejection of record would meet the memory circuit limitations of amended claims 1 (canceled claim 72). With respect to Applicants' comments concerning the reference of Kofidis, the reference discusses electrical stimulation, mechanical stimulation and chemical stimulation (See page 64 column 2, last paragraph, to page 65, column 1, first paragraph, and "Results" section page 63). Clearly one of ordinary skill in the art reviewing this reference would be capable of additionally biologically stimulating the tissue when electrically and/or mechanically stimulating the cardiac tissue. For these reasons, the claims remain rejected.